Pfizer Rises on Q4 Earnings Beat, 2025 Outlook Reaffirmed
Pfizer beats Q4 estimates with 24.9% revenue growth, reaffirming 2025 guidance and targeting $4.5 billion in cost savings ...
Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down
Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...
The Pharma Letter14h
Pfizer beats sales and earnings forecast in 4th-qtr
US pharma giant Pfizer reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial ...
Pfizer beats Q4, FY '24 earnings estimates, stock flat in early trading
Pfizer (PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...
Pfizer Q4 Results Beat Market; Confirms FY25 Outlook - Update
Drug major Pfizer Inc. (PFE), while reporting a profit in its fourth quarter, compared to prior year's loss, on Tuesday reaffirmed ...
Pfizer Beats Q4 Revenue, EPS Estimates
Despite a significant year-over-year decline in Comirnaty revenue, the overall performance was strong, driven by growth in non-COVID-19 products and strategic acquisitions. Pfizer, a renowned ...
Pfizer (NYSE:PFE) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows ...
Pfizer (NYSE:PFE) Price Target Cut to $29.00 by Analysts at Citigroup
Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 ...